This site is intended for health professionals only!

Published on 22 June 2011

Share this story:

New drug prevents graft rejection in kidney transplants

teaser

Bristol-Myers Squibb today announced that the European Commission has granted Marketing Authorisation for NULOJIX® (belatacept), a new biologic agent for the prophylaxis of graft rejection in adult patients receiving a kidney transplant.

Belatacept is the first molecule with a new mechanism of action approved in a decade in kidney transplantation. By acting selectively on the immune system to prevent graft rejection, belatacept helps safeguard renal function, which is increasingly recognised as a key predictor of long term outcomes in kidney transplant recipients, impacting both patient and graft survival.

“One of the key challenges in kidney transplantation has been achieving improvements in renal function that are sustained in the long term,” said Professor Josep Grinyó of the University Hospital of Bellvitge, Spain. “We observe progressive renal function decline in our patients, which may cause additional co-morbidities and result in graft failure. With belatacept’s positive impact on renal function, this approval represents a promising new option for adult kidney transplant patients.”

Approximately 18,000 kidney transplants were performed in the European Union in 2009. As of 31 December 2009, however, more than 50,000 people across the 27 countries were still in need of a kidney transplant. Preserving renal function after transplantation can help avoid a return to dialysis and the need for another transplant.

“As the first new biologic therapy approved for the prevention of graft rejection in kidney transplantation in a decade, Nulojix gives kidney transplant recipients a new innovative treatment option,” said Ron Cooper, President, Europe, Bristol-Myers Squibb. “What we see today with Nulojix is that it helps preserve kidney function after transplantation and we know that this is critical for patients to keep their graft healthier for longer.”

Belatacept, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for the prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen. Belatacept is contraindicated in transplant recipients who are Epstein-Barr virus (EBV) seronegative or serostatus unknown.

The Marketing Authorisation for belatacept follows the positive opinion by the Committee for Human Medicinal Products, which considered that there is a favourable benefit to risk balance for belatacept on the basis of quality, safety and efficacy data submitted.6 The two pivotal Phase III clinical trials (BENEFIT and BENEFIT-EXT) have been extended to seven years in duration and will, upon completion, provide the largest set of controlled long term data of a transplant immunosuppressive regimen to date.

Following approval from the European Commission, belatacept is expected to become commercially available in the European Community in the coming months.

Bristol-Myers Squibb



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: